deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03419897

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

Sponsor: BeiGene

Conditions Hepatocellular Carcinoma (HCC)
Interventions Tislelizumab
Updated 21 times since 2018 Last updated: Oct 23, 2024 Started: Apr 9, 2018 Primary completion: Jun 30, 2021 Completion: Jul 6, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03419897, this PHASE2 trial focuses on Hepatocellular Carcinoma (HCC) and remains completed. Sponsored by BeiGene, it has been updated 21 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

21 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  2. Sep 2022 — Aug 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  8. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Dec 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  12. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  14. Jul 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  15. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beijing, China , Birmingham, United Kingdom , Changchun, China , Clichy, France , Essen, Germany , Greater Manchester, United Kingdom , Guangzhou, China , Hamburg, Germany , Hangzhou, China and 30 more locations